HepQuant to Present at Key Liver Conferences to Highlight Applications of HepQuant DuO™ – a Quantitative Liver Health Test
March 17, 2025Recent clinical data demonstrates how HepQuant DuO test results may be used to inform endoscopy screening decisions, monitor disease progression and evaluate response to resmetirom therapy in patients with compensated advanced chronic liver disease (cACLD).
Denver, CO – March 17, 2025 – HepQuant, LLC continues to expand clinical availability of the HepQuant DuO test to liver specialists in clinical practice, and will present eight abstracts at key upcoming liver conferences, including the 2025 Global Hepatitis Summit in Los Angeles, CA, Liver Connect 2025 in San Antonio, TX, EASL 2025 in Amsterdam, NL, and DDW 2025 in San Diego, CA. These important findings highlight the utility of HepQuant DuO in assessing liver health by quantifying liver function and physiology in patients with cACLD. The test reports the risk of large esophageal varices (LEV’s) and a Disease Severity Index (DSI) risk score to inform the decision to avoid or proceed with endoscopic screening.
Other HepQuant DuO test results include a Hepatic Reserve (HR%) to measure a patient’s current level of liver impairment and a SHUNT% to further evaluate risk of LEV’s, other clinical outcomes and portal systemic shunting. Healthcare providers may use these results to make patient management decisions and to advise their patients in making changes to improve their liver health. To date, HepQuant has published 16 studies supporting the clinical validity and utility of HepQuant DuO testing for patients with cACLD, including those diagnosed with compensated Child-Pugh A cirrhosis, advanced fibrosis, and those suspected of having portal hypertension and varices.
Nationally recognized liver specialists and the HepQuant team will also present the following abstracts and posters to liver specialists at the 2025 Global Hepatitis Summit, Liver Connect, EASL, and DDW conferences.
2025 Global Hepatitis Summit (March 18-21)
Liver Connect 2025 (March 20-22)
- Abstract #47. Gordon, et al. Initial Clinical Experience with the HepQuant DuO Test: Results from the 2023–2024 Early Access Program
- Abstract #22. Imperial, et al. Resmetirom Therapy of MASH-Associated Child Pugh A Cirrhosis Reduces Estimated Risk for Clinical Outcome Based on HepQuant RISK ACE Model
- Abstract #21. Imperial, et al. Pilot Study of a Model Based on Noninvasive Assessments of Portal-Systemic Shunting (HepQuant DuO), Hepatic Fibrosis (FibroScan), and Splenic Congestion (Platelet Count) for Accurate Prediction of Portal Hypertension and Clinically Significant Portal Hypertension
DDW 2025 (May 3-6)
- Abstract #4254901. POSTER OF DISTINCTION. Rahimi, et al. Statins and Metformin may preserve hepatic function and reduce portal-systemic shunting in advanced chronic liver disease: result with the HepQuant DuO
test from the SHUNT-V study - Abstract #4257978. Kim, et al. Quantifying the individual impact of cardiac and liver disease on liver function and portal-systemic shunting in Fontan-associated liver disease by a simplified cholate shunt test
EASL 2025 (May 7-10)
- Abstract 2117. TOP POSTER. Shaked, et al. Quantifying liver function by cholate clearance in extracorporeal circuits with a genetically modified porcine liver and brain-dead human decedent
- Abstract 2138. Kim, et al. The HepQuant DuO test finds linkage between liver blood flow, portal-systemic shunting and cardiac hemodynamics in Fontan-associated liver disease
Dr. Gregory Everson, CEO of HepQuant, shared: “It is exciting to witness the heightened enthusiasm from practicing physicians and our pharma colleagues about the commercially available HepQuant DuO™ test. We are dedicated to improving patient lives by providing quantitative measures of liver health.”
About HepQuant
HepQuant has developed minimally invasive diagnostic tests that quantify liver health and enable healthcare providers to treat people with liver disease more effectively by measuring disease severity and progression. Knowing where a patient falls on the disease spectrum informs personalized treatment decisions for that individual. HepQuant is a privately held diagnostics company based in Denver, Colorado. Learn more at HepQuant.com
HepQuant DuO is a Laboratory Developed Test (LDT). This test was developed and its performance characteristics determined by HepQuant, LLC in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
Contact
Joellyn Enos, Chief Commercial Officer
Joellyn.Enos@HepQuant.com
303.268.7069